.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,303,988

« Back to Dashboard

Details for Patent: 8,303,988

Title:Antifungal once-a-day product, use and formulation thereof
Abstract: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the C.sub.max for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C.sub.max at different times.
Inventor(s): Rudnic; Edward M. (N. Potomac, MD), Isbister; James D. (Potomac, MD), Treacy, Jr.; Donald J. (Annapolis, MD), Wassink; Sandra E. (Frederick, MD)
Assignee: Shionogi Inc. (Florham Park, NJ)
Filing Date:Sep 16, 2010
Application Number:12/884,050
Claims:1. A once-a-day antifungal product comprising: first, second, and third dosage forms, wherein each of said dosage forms includes at least one antifungal agent and a pharmaceutically acceptable carrier; said first dosage form is an immediate release dosage form; said second and third dosage forms are delayed release dosage forms; each of said first, second, and third dosage forms initiates release of said at least one antifungal agent at different times; Cmax in serum of the total antifungal agent released from said antifungal product is achieved in less than about 12 hours from administration; and said once-a-day antifungal product contains the total dosage of said at least one antifungal agent for a twenty-four hour period.

2. The product of claim 1, wherein the Cmax of the total antifungal agent released from said antifungal product is reached no earlier than four hours after administration.

3. The product of claim 1, wherein the antifungal agent released from the first dosage form reaches a Cmax in serum within from about 0.5 hours to about 2 hours after administration of the product.

4. The product of claim 1, wherein the antifungal agent released from the second dosage form reaches a Cmax in serum in no more than about 4 hours after administration of the product.

5. The product of claim 1, wherein the antifungal agent released from the third dosage form reaches a Cmax in serum within 8 hours after administration of the product.

6. The product of claim 1, wherein the immediate release dosage form contains at least 20% and no more than 50% of the total dosage of antifungal agent.

7. The product of claim 1, wherein the product is an oral dosage form.

8. The product of claim 7, wherein the antifungal agent released from the second dosage form reaches a Cmax in the serum after Cmax is reached in the serum for the antifungal agent released from the first dosage form.

9. The product of claim 8, wherein the antifungal agent released from the third dosage form reaches a Cmax in the serum after Cmax is reached in the serum for the antifungal agent released from the second dosage form.

10. The product of claim 9, wherein said second dosage form initiates release of said antifungal agent before said third dosage form, wherein said second dosage form provides from 30% to 60% by weight of the total antifungal released by said second and third dosage forms, and wherein said third dosage form provides the remainder of the total antifungal agent released by said second and third dosage forms.

11. The product of claim 1 further comprising a fourth antifungal dosage form, said fourth antifungal dosage form comprising at least one antifungal agent and a pharmaceutically acceptable carrier and wherein said at least one antifungal agent released from said fourth antifungal dosage form reaches a Cmax in the serum after Cmax is achieved in the serum for antifungal agent released from each of said first, second, and third dosage forms.

12. The product of claim 11, wherein said fourth antifungal dosage form is a delayed release dosage form.

13. The product of claim 12, wherein said second dosage form initiates release of said antifungal agent before said third dosage form, wherein said third dosage form initiates release of said antifungal agent before said fourth dosage form, wherein said second dosage form provides 20% to 35% by weight of the total antifungal agent released by said second, third, and fourth dosage forms, wherein said third dosage form provides from 20% to 40% by weight of the total antifungal agent released by said second, third, and fourth dosage forms, and wherein said fourth dosage form provides the remainder of the total antifungal agent released by said second, third, and fourth dosage forms.

14. The product of claim 11, wherein the antifungal agent released from the first dosage form reaches a Cmax in serum within from about 0.5 hours to about 2 hours after administration of the product.

15. The product of claim 11, wherein the antifungal agent released from the second dosage form reaches a Cmax in serum in no more than about 4 hours after administration of the product.

16. The product of claim 11, wherein the antifungal agent released from the third dosage form reaches a Cmax in serum within 8 hours after administration of the product.

17. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 1 once-a-day.

18. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 2 once-a-day.

19. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 3 once-a-day.

20. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 4 once-a-day.

21. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 5 once-a-day.

22. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 6 once-a-day.

23. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 7 once-a-day.

24. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 8 once-a-day.

25. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 9 once-a-day.

26. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 10 once-a-day.

27. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 11 once-a-day.

28. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 12 once-a-day.

29. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 13 once-a-day.

30. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 14 once-a-day.

31. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 15 once-a-day.

32. A process for treating a fungal infection in a host comprising: administering to a host the antifungal product of claim 16 once-a-day.

33. The product of claim 11, wherein the Cmax of the total antifungal agent released from said antifungal product is reached no earlier than four hours after administration.

34. The product of claim 11, wherein the product is an oral dosage form.

35. The product of claim 34, wherein the antifungal agent released from the second dosage form reaches a Cmax in serum after Cmax is reached for the antifungal agent released from the first dosage form.

36. The product of claim 35, wherein the antifungal agent released from the third dosage form reaches a Cmax in serum after Cmax is reached for the antifungal agent released from the second dosage form.

37. A process for treating fungal infection in a host comprising administering to a host the antifungal product of claim 33 once-a-day.

38. A process for treating a fungal infection in a host comprising administering to a host the antifungal product of claim 34 once-a-day.

39. A process for treating a fungal infection in a host comprising administering to a host the antifungal product of claim 35 once-a-day.

40. A process for treating a fungal infection in a host comprising administering to a host the antifungal product of claim 36 once-a-day.

41. A once-a-day antifungal product for oral administration comprising: first, second, and third dosage forms, wherein each of said dosage forms includes at least one antifungal agent and a pharmaceutically acceptable carrier; said first dosage form is an immediate release dosage form; said second and third dosage forms are delayed release dosage forms; each of said first, second and third dosage forms initiates release of said at least one antifungal agent at different times; Cmax in serum of the total antifungal agent released from said antifungal product is achieved in less than about 12 hours from administration; and said once-a-day antifungal product contains the total dosage of said at least one antifungal agent for a twenty-four hour period.

42. A process for treating a fungal infection in a host comprising administering to a host the antifungal product of claim 41 once-a-day.

43. The product of claim 1, wherein each of said dosage forms includes only one antifungal agent.

44. The product of claim 43, wherein each of said dosage forms has the same antifungal agent.

45. The product of claim 41, wherein the Cmax of the total antifungal agent released from said antifungal product is reached no earlier than 4 hours after administration.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc